ORIGINAL ARTICLE   

Journal of Neurosurgical Sciences 2025 February;69(1):102-10

DOI: 10.23736/S0390-5616.23.06107-6

Copyright © 2023 EDIZIONI MINERVA MEDICA

lingua: Inglese

Longitudinal impact of intracerebral low-grade glioma disease on health-related quality of life

Laurèl RAUSCHENBACH ^{1, 2, 3} ✉, Pauline BARTSCH ¹, Alejandro N. SANTOS ^{1, 3}, Anna MICHEL ^{1, 3}, Hanah H. GULL ^{1, 3}, Pikria KETELAURI ^{1, 3}, Marvin DARKWAH OPPONG ^{1, 3}, Börge SCHMIDT ⁴, Celia DOBERSALSKE ², Tobias BLAU ⁵, Yahya AHMADIPOUR ^{1, 3}, Ramazan JABBARLI ^{1, 3}, Karsten H. WREDE ^{1, 3}, Ulrich SURE ^{1, 3}, Philipp DAMMANN ^{1, 3}

¹ Department of Neurosurgery and Spine Surgery, University Hospital of Essen, Essen, Germany; ² DKFZ Division Translational Neurooncology at the West German Cancer Center (WTZ), DKTK Partner Site, University Hospital of Essen, Essen, Germany; ³ Center for Translational Neuroscience and Behavioral Science (C-TNBS), University of Duisburg-Essen, Essen, Germany; ⁴ Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, Essen, Germany; ⁵ Institute for Neuropathology, University Hospital of Essen, Essen, Germany

BACKGROUND: The aim of this study was to assess health-related quality of life (HRQOL) before and after treatment for intracerebral low-grade glioma.
METHODS: Patients with low-grade glioma who underwent surgical tumor removal between 2012 and 2018 were eligible for this study. All individuals and their closest relatives received thorough preoperative (RESULTS: A total of 25 patients were referred for further analysis, after adjustment to the 2021 WHO classification for central nervous system tumors. Compared to the values of a healthy reference population, the patients expressed significant limitations in several SF36 items, both before and after treatment. Under treatment, there were no significant changes in the SF36 items, but the ALQI questionnaire indicated decreasing HRQOL over time. Data derived from relatives revealed a high degree of concordance with the rating results of the patients. Univariate analysis identified neurological deterioration and ongoing epileptic seizures as predictors for unfavorable HRQOL after one year.
CONCLUSIONS: Low-grade glioma disease has a significant impact on HRQOL and treatment might contribute to further deterioration. New-onset neurological deficits and ongoing epileptic seizures are predictors of limitations in quality of life. Since the results are based on a small cohort with limited follow-up time, the generalizability of these statements is limited and further studies are required.

KEY WORDS: Glioma; Quality of life; Outcome; Therapeutics